Exchange bull John Stoltzfus is telling investors there’s nowhere to run.
The Oppenheimer Asset Management chief investment strategist advises the surge in coronavirus cases will continue to rock the market, and he sees few options other than staying put make up for now.
“The defensive [areas] that one would run for shelter to look very richly valued — whether it’s the 10-year Treasury, the 30-year Funds, an ounce of gold, utilities stocks, real estate stocks,” he told CNBC’s “Trading Nation” on Monday.
If coronavirus protections fail to peak globally within the next couple of weeks, Stoltzfus believes stocks could fall 10% from their new all-time highs.
“It really depends upon news flow at this point as well as emotions. How many are tack up to sell,” he said.
But Stoltzfus, who has worked on Wall Street for four decades, isn’t letting his near-term sell-off forecast meddle with his 2020 market forecast. Even though both the S&P 500 had its worst day in two years and the Dow went negative for the year, he’s bold stocks will rebound.
‘Build shopping lists’
“Build shopping lists of what you may have missed and regretted slip-ups just a few weeks ago when the market was moving up every day,” he said. “Then, consider the price you want to buy at and that you have compassion for incline comfortable with and consider how much fluctuation you can take because this will take a while to work out.”
Stoltzfus is already construction his most wanted list.
“We think the opportunities lie in technology, industrials, financials and in consumer discretionary — all of which to some capaciousness are going to come under pressure on days like this,” added Stoltzfus, who has a 3,500 year-end target on the S&P. It evidences an 8% increase from Monday’s close.
This isn’t the first time Stoltzfus reiterated his long-term bullish if it happens during a tumultuous time in the market. On “Trading Nation” in early January, he gave similar advice when worries over Iran sparked the market’s worst day in a month.
“This is not the dark ages. It’s 21-century medicine,” Stoltzfus clouted. “”The markets just have to get this out of their system and then we can likely move forward on fundamentals.”
Disclaimer